Introduction
DFUs, amputation, Diabetic foot ulcers, gangrene, ulcer, diabetes
RECURRENCE, HEALED ULCER, DIABETIC FOOT ULCERS, GANGRENE, ULCER, COMPLICATIONS, DIABETES
Diabetic foot ulcers (DFUs) are among the most serious complications among patients with diabetes. The estimated lifetime incidence of a DFU is 19% to 34%, and roughly 40% to 65% of patients with diabetes undergo recurrence within 1 to 5 years after ulcer healing.To ameliorate health and economic burdens of DFUs, the primary treatment goals include accelerating wound healing, remaining longer in the healing state (ie, a healed ulcer), and preventing gangrene and amputation.ON101 is a first-in-class novel drug to treat DFUs through regulating M1/M2 macrophages.Although the promising efficacy and safety of ON101 were observed in a short-run trial, it remains unknown whether the use of ON101 could provide longer-term economic benefits of treating DFUs. We conducted a computer simulation model to assess the cost-effectiveness of ON101 added on to general wound care (GWC) vs GWC alone for DFUs from the Taiwan health care sector perspective.